Thus, such drug combination therapy can be effective for drug-resistant lung cancer and enables to overcome resistance that often occurs after 9–13 months of EGFR TKIs administration in NSCLC [220]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.